Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00302003 · OUTCOME

Event Free Survival (EFS)

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma · Source last updated 2021-03-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Probability of survival
Interval / dispersion
95% Confidence Interval
Time frame
At 60 months

What was measured

Survival is defined as the minimum time from study entry to a relapse of any kind, death from any cause, or occurrence of a second malignant neoplasm. Patients without report of such events where censored at last contact. This will be used to compute event free survival (EFS).

Analysis population: Eligible (n=278). Follow-up for censored patients (n=223) is 75 months (range: 4.7 to 108 months).

Groups in this outcome

Group 1

Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Group 1278

Reported measurements

Source class 1
Values in Probability of survival · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Group 10.79Not reported0.740.84Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.74
        upper Limit
        0.84
        value
        0.79
denoms
  1. counts
    1. group Id
      OG000
      value
      278
    units
    Participants
description
Survival is defined as the minimum time from study entry to a relapse of any kind, death from any cause, or occurrence of a second malignant neoplasm. Patients without report of such events where censored at last contact. This will be used to compute event free survival (EFS).
dispersion Type
95% Confidence Interval
groups
  1. description
    Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim
    id
    OG000
    title
    Group 1
param Type
NUMBER
population Description
Eligible (n=278). Follow-up for censored patients (n=223) is 75 months (range: 4.7 to 108 months).
reporting Status
POSTED
time Frame
At 60 months
title
Event Free Survival (EFS)
type
PRIMARY
unit Of Measure
Probability of survival

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice